Review| Volume 14, ISSUE 4, P271-276, August 2016

A Systematic Review of the Prognostic Role of Hematologic Scoring Systems in Patients With Renal Cell Carcinoma Undergoing Nephrectomy With Curative Intent

Published:January 21, 2016DOI:


      The objective is to evaluate the prognostic benefit of the Glasgow Prognostic Score (GPS), neutrophil–lymphocyte ratio (NLR), platelet–lymphocyte ratio (PLR), and Prognostic Nutrition Index (PNI) in patients with localized renal cell carcinoma undergoing nephrectomy with curative intent. Embase and MEDLINE databases were searched for all publications before April 2015. Duplicates were excluded, and inclusion/exclusion criteria were applied to all abstracts; of those remaining, full articles were obtained and inclusion/exclusion criteria were again applied, and the remaining articles were included and critically appraised. Eight articles were included in this review. Three articles were included for GPS. Outcomes included recurrence-free survival, cancer-specific survival (CSS), and overall survival (OS). All articles demonstrated better prognosis associated with a lower GPS on multivariate analysis: 1-year recurrence-free survival hazard ratio (HR), 7.0 (P = .001); CSS HR, 6.7 to 8.6 (P < .001); and OS HR 4.2 (P < .001). Four articles were included for NLR. All articles demonstrated elevated NLR to be associated with a poorer prognosis. Two articles demonstrated elevated NLR to be associated with a lower progression-free survival. One article demonstrated elevated NLR to be associated with a lower CSS (HR, 1.02, P = .009), and 2 articles demonstrated elevated NLR to be associated with a lower OS (HR, 1.02-1.6). No articles were included for PLR, and only 1 article was identified for PNI. There may be a role for modified GPS and NLR in patients with renal cell carcinoma undergoing nephrectomy with curative intent. Evidence for PLR and PNI is minimal.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Cancer Research UK. Kidney cancer incidence statistics. Available at: Accessed June 6, 2015.

        • Dirican A.
        • Kucukzeybek Y.
        • Somali I.
        • et al.
        The association of hematologic parameters on the prognosis of patients with metastatic renal cell carcinoma.
        J BUON. 2013; 18: 413-419
        • Jagdev S.P.
        • Gregory W.
        • Vasudev N.S.
        • et al.
        Improving the accuracy of pre-operative survival prediction in renal cell carcinoma with C-reactive protein.
        Br J Cancer. 2010; 103: 1649-1656
        • Bukowski R.M.
        Prognostic factors for survival in metastatic renal cell carcinoma: update 2008.
        Cancer. 2009; 115: 2273-2281
        • Lam J.S.
        • Leppert J.T.
        • Belldegrun A.S.
        • Figlin R.A.
        Novel approaches in the therapy of metastatic renal cell carcinoma.
        World J Urol. 2005; 23: 202-212
        • Janzen N.K.
        • Kim H.L.
        • Figlin R.A.
        • Bellegrun A.S.
        Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease.
        Urol Clin North Am. 2003; 30: 843-852
        • Rouviere O.
        • Bouvier R.
        • Negrier S.
        • Badet L.
        • Lyonnet D.
        Nonmetastatic renal-cell carcinoma: is it really possible to define rational guidelines for post-treatment follow-up?.
        Nat Clin Pract Oncol. 2006; 3: 200-213
      2. British Association of Urological Surgeons. Multi-disciplinary team (MDT) guidance for managing renal cancer. Available at: Accessed June 6, 2015.

        • McMillan D.C.
        The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer.
        Cancer Treat Rev. 2013; 39: 534-540
        • Guthrie G.J.
        • Charles K.A.
        • Roxburgh C.S.
        • Horgan P.G.
        • McMillan D.C.
        • Clarke S.J.
        The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer.
        Crit Rev Oncol Hematol. 2013; 88: 218-230
        • Roxburgh C.S.
        • McMillan D.C.
        Role of systemic inflammatory response in predicting survival in patients with primary operable cancer.
        Future Oncol. 2010; 6: 149-163
        • Onodera T.
        • Goseki N.
        • Kosaki G.
        Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients.
        Nihon Geka Gakkai Zasshi. 1984; 85: 1001-1005
        • Ramsey S.
        • Lamb G.W.
        • Aitchison M.
        • Graham K.
        • McMillan D.C.
        Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer.
        Cancer. 2007; 109: 205-212
        • Ramsey S.
        • Aitchison M.
        • Graham J.
        • McMillan D.C.
        The longitudinal relationship between the systemic inflammatory response, circulating T-lymphocytes, interleukin-6 and -10 in patients undergoing immunotherapy for metastatic renal cancer.
        BJU Int. 2008; 102: 125-129
        • Dirican A.
        • Kucukzeybek Y.
        • Erten C.
        • et al.
        Prognostic and predictive value of hematologic parameters in patients with metastatic renal cell carcinoma: second line sunitinib treatment following IFN-alpha.
        Asian Pac J Cancer Prev. 2013; 14: 2101-2105
      3. Critical appraisal skills programme (CASP). CASP cohort study check list. Available at: Accessed June 6, 2015.

        • Lamb G.W.
        • Aitchison M.
        • Ramsey S.
        • Housley S.L.
        • McMillan D.C.
        Clinical utility of the Glasgow Prognostic Score in patients undergoing curative nephrectomy for renal clear cell cancer: basis of new prognostic scoring systems.
        Br J Cancer. 2012; 106: 279-283
        • Qayyum T.
        • McArdle P.A.
        • Lamb G.W.
        • et al.
        Prospective study of the role of inflammation in renal cancer.
        Urol Int. 2012; 88: 277-281
        • Tai C.G.
        • Johnson T.V.
        • Abbasi A.
        • et al.
        External validation of the modified Glasgow prognostic score for renal cancer.
        Indian J Urol. 2014; 30: 33-37
        • De Martino M.
        • Pantuck A.J.
        • Hofbauer S.
        • et al.
        Prognostic impact of preoperative neutrophil-to-lymphocyte ratio in localized nonclear cell renal cell carcinoma.
        J Urol. 2013; 190: 1999-2004
        • Pichler M.
        • Hutterer G.C.
        • Stoeckigt C.
        • et al.
        Validation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients.
        Br J Cancer. 2013; 108: 901-907
        • Sejima T.
        • Iwamoto H.
        • Morizane S.
        • et al.
        The significant immunological characteristics of peripheral blood neutrophil-to-lymphocyte ratio and Fas ligand expression in nephrectomised tumor in late recurrence from renal cell carcinoma.
        Urol Oncol. 2013; 31: 1343-1349
        • Viers B.R.
        • Houston Thompson R.
        • Boorjian S.A.
        • et al.
        Preoperative neutrophil-lymphocyte ratio predicts death among patients with localized clear cell renal carcinoma undergoing nephrectomy.
        Urol Oncol. 2014; 32: 1277-1284
        • Hofbauer S.L.
        • Pantuck A.J.
        • de Martino M.
        • et al.
        The preoperative prognostic nutritional index is an independent predictor of survival in patients with renal cell carcinoma.
        Urol Oncol. 2015; 33: 68e1-68e7
        • McMillan D.C.
        An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer.
        Proc Nutr Soc. 2008; 67: 257-262